Cas:14678-78-5 5-(1H-benzimidazol-2-yl)pentanoic acid manufacturer & supplier

We serve Chemical Name:5-(1H-benzimidazol-2-yl)pentanoic acid CAS:14678-78-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-(1H-benzimidazol-2-yl)pentanoic acid

Chemical Name:5-(1H-benzimidazol-2-yl)pentanoic acid
CAS.NO:14678-78-5
Synonyms:5-benzimidazol-2-ylpentanoic acid;5-(1H-benzoimidazol-2-yl)-pentanoic acid;5-(1H-1,3-benzodiazol-2-yl)pentanoic acid;5-(1H-Benzimidazol-2-yl)-valeriansaeure;5-(1H-benzimidazol-2-yl)-valeric acid;5-(2-Benzimidazolyl)-valeriansaeure
Molecular Formula:C12H14N2O2
Molecular Weight:218.25200
HS Code:2933290090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:504.1ºC at 760 mmHg
Density:1.268g/cm3
Index of Refraction:1.635
PSA:65.98000
Exact Mass:218.10600
LogP:2.36030

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-benzimidazol-2-ylpentanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(2-Benzimidazolyl)-valeriansaeure physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(2-Benzimidazolyl)-valeriansaeure Use and application,5-benzimidazol-2-ylpentanoic acid technical grade,usp/ep/jp grade.


Related News: The company reported that it was cooperating with the Justice Department probe and that an outside law firm was also “investigating these allegations thoroughly.” 5-(1H-benzimidazol-2-yl)pentanoic acid manufacturer Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. 5-(1H-benzimidazol-2-yl)pentanoic acid supplier The FDA regulates cosmetics, but the cosmetics industry itself is responsible for assessing the health and safety of ingredient, and there’s not much FDA oversight of that process,” Bruton said.
The Personal Care Products Council, which represents the cosmetics industry, did not have comment on the findings.
A new study finds that many mass shooters in America suffered from a mental illness that wasn’t being treated when they committed their crime.
“Without losing sight of the larger perspective that most who are violent are not mentally ill, and most of the mentally ill are not violent, our message is that mental health providers, lawyers and the public should be made aware that some unmedicated patients do pose an increased risk of violence,” wrote researchers led by Dr. Ira Glick, from Stanford University’s School of Medicine.
Glick’s team studied 35 mass shooting cases that occurred in the United States between 1982 and 2019 and involved shooters who survived and were brought to trial.
Analysis of various sources of medical evidence on the mass shooters showed that 28 had mental illness diagnoses. Eighteen had schizophrenia and 10 had other diagnoses including bipolar disorder, delusional disorder, personality disorders and substance-related disorders.
Of the 28 shooters with a mental illness diagnosis, none were medicated or received other treatment for their disorders prior to their crimes, according to the study published recently in the Journal of Clinical Psychopharmacology.
Glick and his colleagues also examined 20 mass shooters who died at the crime scene and found that eight had schizophrenia, seven had other mental health diagnoses, and five had unknown diagnoses. None were receiving appropriate medications.
The investigators pointed out that despite the high frequency of mass shooting events in the United States, there has been almost no medical research on the nature and incidence of mental illness among people who commit these crimes.
“The psychiatric disorders seen in perpetrators of mass shootings are serious brain illnesses — as much in need of proper diagnosis and treatment as heart disease or any other medical condition,” the authors noted in a Stanford news release.
“We need to reduce the stigma associated with these diseases to enable patients to receive appropriate and adequate psychiatric medication and other treatments,” they added, “by actually talking to patients and their significant others, we have the opportunity to save lives. 5-(1H-benzimidazol-2-yl)pentanoic acid vendor Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. 5-(1H-benzimidazol-2-yl)pentanoic acid factory Vietnam recently barred almost all flights to and from mainland China, Hong Kong and Macau until May 1, according to the United States Federal Aviation Administration.